Die Onkologie pp 399-424 | Cite as

Zytostatische Chemotherapie

  • R. Pirker

Zusammenfassung

Die zytostatische Chemotherapie hat in den letzten Jahrzehnten eine rasante Entwicklung durchgemacht. Sie hat zu entscheidenden Fortschritten in der Behandlung hämatologischer Neoplasien geführt und ist auch bei etwa der Hälfte der soliden Tumoren effektiv.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Adjei AA (2000) Signal transduction pathway targets for anticancer drug discovery. Curr Pharm Des 6: 361–78PubMedCrossRefGoogle Scholar
  2. Advani R, Visani G, Milligan D et al.(1999)Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone,etoposide,and cytarabine (PSC-MEC). Adv Exp Med Biol 457: 47–56CrossRefGoogle Scholar
  3. Ambudkar SV, Dey S, Hrycyna CA, Rämachandra M, Pastan I, Gottesman MM (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39: 361–398PubMedCrossRefGoogle Scholar
  4. Barreff MW (1998) Chemoradiation for rectal cancer: current methods. Semin Surg Oncol 15: 114–119CrossRefGoogle Scholar
  5. Baselga J, Averbuch SD (2000) ZD1839 (“Iressa”) as an anticancer agent. Drugs 60 [Suppl 1]: 33; discussion 41–42Google Scholar
  6. Belani CP, Ramanathan RK (1 998) Combined-modality treatment of locally advanced non-small cell lung cancer: incorporation of novel chemotherapeutic agents. Chest 113 [Suppl 11: 535–60SGoogle Scholar
  7. Berger T, Malayeri R, Doppelbauer A, Krajnik G, Huber H, Auff E, Pirker R (1997) Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy. Eur J Cancer 33: 1393–1399PubMedCrossRefGoogle Scholar
  8. Blumenschein GR, DiStefano A, Caderao J, Fristenberg B, Adams J, Schweichler LH, Drinkard L (1997) Multimodality therapy for locally advanced and limited stage IV breast cancer: the impact of effective non-cross-resistance late-consolidation chemotherapy. Clin Cancer Res 3: 2633–2637PubMedGoogle Scholar
  9. Borsi JD, Sagen E, Romslo I, Moe PJ (1990) Rescue after intermediate and high-dose methotrexate: background, rationale, and current practice. Pediatr Hematol Oncol 7: 347–363PubMedCrossRefGoogle Scholar
  10. Bunn PA Jr, Crowley J, Kelly K et al. (1995) Chemoradiotherapy with or without granulocytemacrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase Ill randomized study of the Southwest Oncology Group. J Clin Oncol 13: 1632–1641PubMedGoogle Scholar
  11. Calvert AH, Newell DR, Gumbrell LA et al. (1989) Carboplatin dosage: prospective evaluation of a simple formula based an renal function. J Clin Oncol 7: 1748–1756PubMedGoogle Scholar
  12. Carew JF, Shah JP (1998) Advances in multimodality therapy for laryngeal cancer. CA Cancer J Clin 48: 211–228PubMedCrossRefGoogle Scholar
  13. Charbit A, Malaise EP,Tubiana M (1971) Relationship between the pathological nature and the growth rate of human tumors. Eur J Cancer 7: 307Google Scholar
  14. Clayman GL (2000) The current status of gene therapy. Semin Oncol 27 [Suppl 8]: 39–43PubMedGoogle Scholar
  15. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31–41PubMedCrossRefGoogle Scholar
  16. Coley HM,Twentyman PR, Workman P (1990) 9-Alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance. EurJ Cancer 26: 665–667Google Scholar
  17. Conley BA,Van Echo DA (1992) Antineoplastic drug development.ln: Perry MC (ed) The chemotherapy source book. Williams & Wilkins, Baltimore, pp 15–21Google Scholar
  18. Cooper MR, Cooper MR (1991) Principles of medical oncology.ln:Holleb AI, Fink DJ, Murphy GP ( 1991 ) American Cancer Society Textbook of Oncology.The American Cancer Society, AtlantaGoogle Scholar
  19. Covelli A (1999) Modulation of multidrug resistance (MDR) in hematological malignancies. Ann Oncol 10 [Supp16]: 53–59PubMedCrossRefGoogle Scholar
  20. Dalgleish AG (2000) Cancer vaccines. Br J Cancer 82: 1619–1624PubMedCrossRefGoogle Scholar
  21. Dempke W, Voigt W, Grothey A, Hill BT, Schmoll HJ (2000) Cisplatin resist-ance and oncogenes–a review. Anticancer Drugs 11: 225–236PubMedCrossRefGoogle Scholar
  22. Dodion P, Kenis Y, Staquet M (1986) Phase I trials of single agents in adult solid tumours: preclinical and clinical aspects. Drugs Exp Clin Res 12: 23–30PubMedGoogle Scholar
  23. Eberhardt W, Wilke H, Stamatis G et al. (1998) Preoperative chemotherapy followed by concurrent chemoradiation therapy based an hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer:mature results of a phase Il trial. J Clin Oncol 16: 622–634PubMedGoogle Scholar
  24. Eberhardt W, Stamatis G, Stuschke M et al. (1999) Prognostically orientated multimodality treatment including surgery for selected patients of small-cell lung cancer patients stages IB to IIIB: long-term results of a phase II trial. Br J Cancer 81: 1206–1212PubMedCrossRefGoogle Scholar
  25. Edler L (1990) Statistical requirements of phase I studies. Onkologie 13: 90–95PubMedCrossRefGoogle Scholar
  26. Eisenhauer EA, O’Dwyer Pi, Christian M, Humphrey JS (2000) Phase I clinical trial design in cancer drug development. J Clin Oncol 18: 684–692PubMedGoogle Scholar
  27. EORTC Pharmacokinetics and Metabolism Group (1987) Pharmacokinetically guided dose escalation in phase 1 clinical trials. Commentary and proposed guidelines. Eur J Cancer Clin Oncol 23: 1083–1087CrossRefGoogle Scholar
  28. Feldman AL, Libutti SK (2000) Progress in antiangiogenic gene therapy of cancer. Cancer 89: 1181–1194PubMedCrossRefGoogle Scholar
  29. Filipits M,Suchomel RW,Zöchbauer S, Malayeti R,Pirker R (1996) Clinical relevance of drug resistance genes in malignant diseases. Leukemia 10: S10 - S17Google Scholar
  30. Filipits M, Pohl G, StranzlTet al. (1998). Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood 91: 1508–1513PubMedGoogle Scholar
  31. Filipits M, Drach J, Pohl G et aí. (1999) Expression of the lung resistance protein predicts poor outcome in patients with multiple myeloma. Clin Cancer Res 5: 2426–2430PubMedGoogle Scholar
  32. Filipits M, Jaeger U, Simonitsch I, Chizzali-Bonfadin C, Heinzl H, Pirker R (2000a) Clinical relevance of the lung resistance protein in diffuse large B-cell lymphomas. Clin Cancer Res 6: 3417–3423PubMedGoogle Scholar
  33. Filipits M, Stranzl T, Pohl G et al. (2000b) Drug resistance factors in acute myeloid leukemia: a comparative analysis. Leukemia 1 4: 68–76CrossRefGoogle Scholar
  34. Fuse E, Kobayashi S, Inaba M, Suzuki H, Sugiyama Y (1994) Application of pharmacokinetically guided dose escalation with respect to cell cycle phase specificity.) Natl Cancer Inst 86: 989–996Google Scholar
  35. Gokbuget N, Hoelzer D (1996) High-dose methotrexate in the treatment of adult acute lymphoblastic leukemia. Ann Hematol 72: 194–201PubMedCrossRefGoogle Scholar
  36. Gordon AN,Granai CO,Rose PG etal. (2000) Phase II studyof liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 18: 3093–3100Google Scholar
  37. Gosland M, Lum B, Schimmelpfennig J, Baker J, Doukas M (1996) Insights into mechanisms ofcisplatin resistance and potential for its clinical reversal. Pharmacotherapy 16: 16–39PubMedGoogle Scholar
  38. Graham MA,Workman P (1992)The impact of pharmacokinetically guided dose escalation strategies in phase I clinical trials: critical evaluation and recommendations for future studies. Ann Oncol 3:339–347Google Scholar
  39. Gralla RJ, Osoba D, Kris M (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology.) Clin Oncol 17: 2971–2994Google Scholar
  40. Green MC, Murray JL, Hortobagyi GN (2000) Monoclonal antibody therapy for solid tumors. Cancer Treat Rev 26: 269–286PubMedCrossRefGoogle Scholar
  41. Greene MH, Boice JD Jr, Greer BE, Blessing JA, Dembo AJ (1982) Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer:a study of five randomized clinical trials. N Engl J Med 307: 1416–1421PubMedCrossRefGoogle Scholar
  42. Grem JL (2000) 5-Fluorouracil:forty-plus and still ticking.A review of its pre-clinical and clinical development. Invest New Drugs 18:299–313Google Scholar
  43. Grunberg SM, Hesketh PJ (1993) Control of chemotherapy-induced eme-sis. N Engl J Med 329: 1790–1796PubMedCrossRefGoogle Scholar
  44. Ham SJ, van der Graaf WT, Pras E, Molenaar WM, van den Berg E, Hoekstra HJ (1 998) Soft tissue sarcoma of the extremities. A multimodality diagnostic and therapeutic approach. Cancer Treat Rev 24: 373–391Google Scholar
  45. Hensley ML, Schuchter LM, Lindley C et al. (1999) American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 17: 3333–3355PubMedGoogle Scholar
  46. Hochster H, Liebes L,Wadler Set aí. (1992) Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin.J Natl Cancer Inst 84: 1725–1730Google Scholar
  47. Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ,Yang CP (1993) Taxol: mecha- nisms of action and resistance.) Natl Cancer Inst Monogr 15: 55–61Google Scholar
  48. Jelliffe RW (1971) Estimation of creatinine clearance when urine cannot be collected. Lancet 1: 975–976PubMedCrossRefGoogle Scholar
  49. Kandioler-Eckersberger D, Kappel S, Mittlbock M et al. (1999) The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer.) Thorac Cardiovasc Surg 117: 744–750Google Scholar
  50. Karakousis CP, Driscoll DL (1999) Treatment and local control of primary extremity soft tissue sarcomas.J Surg Onco171:155–161Google Scholar
  51. Kelsen DP (2000) Multimodality therapy of esophageal cancer:an update. Cancer J Sci Am 6 [Supp12]: 177–181Google Scholar
  52. Knox SJ, Meredith RF (2000) Clinical radioimmunotherapy. Semin Radiat Oncol 10: 73–93PubMedCrossRefGoogle Scholar
  53. Krajnik G, Mohn-Staudner A, Thaler J et al. (2000) Vinorelbine-gemcitabine in advanced non-small-cell lung cancer (NSCLC):an AASLC phase II tri-al. Austrian Association for the Study of Lung Cancer. Ann Oncol 11: 993–998PubMedCrossRefGoogle Scholar
  54. Kuss B, Cotter F (1999) Antisense–time to shoot the messenger. Ann Onco1 10: 495–503CrossRefGoogle Scholar
  55. La Quaglia MP (1998) Osteosarcoma.Specific tumor management and results. Chest Surg Clin N Am 8: 77–95PubMedGoogle Scholar
  56. Lebwohl DE, Canetta R (1999) New developments in chemotherapy of advanced breast cancer. Ann Oncol 10 [Suppl 6]: 139–146PubMedCrossRefGoogle Scholar
  57. Lehnert T (1999) Multimodal therapy for squamous carcinoma of the oesophagus. Br J Surg 86: 727–739PubMedCrossRefGoogle Scholar
  58. Lerut T, Coosemans W, De Leyn P, Van Raemdonck D, Deneffe G, Decker G (1999) Treatment of esophageal carcinoma. Chest 116 [Suppl 6]: 4635–4655Google Scholar
  59. Lombardi F, Navarria P,Gandola L (1998)Theevolving role of radiation therapy in the optimal multimodality treatment of childhood cancer.Tumori 84:270–273Google Scholar
  60. Malayeri R, Filipits M, Suchomel RW, Zöchbauer S,Lechner K, Pirker R (1996) Multidrug resistance genes in leukemias and its reversal. Leukemia Lymphoma 23: 451–458CrossRefGoogle Scholar
  61. Marie JP, Zittoun R, Sikic BI (1991) Multidrug resistance (mdrl) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 78: 586–592PubMedGoogle Scholar
  62. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207–214PubMedCrossRefGoogle Scholar
  63. Ozer H, Armitage JO, Bennett CL et al. (2000) 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.) Clin Oncol 18: 3558–3585Google Scholar
  64. Pastan I, Gottesman MM (1991) Multidrug resistance. Annu Rev Med 42: 277–286PubMedCrossRefGoogle Scholar
  65. Pastan I (1997) Targeted therapy of cancer with recombinant immunotoxins. Biochim Biophys Acta 1333: C1–6PubMedGoogle Scholar
  66. Patterson W, Reams GP (1992) Renal toxicities of chemotherapy.Semin On-col 19: 521–528Google Scholar
  67. Perry MC (1992) Chemotherapeutic agents and hepatotoxicity.Semin On-col 19: 551–565Google Scholar
  68. Pirker R, FitzGerald DJ, Handton TC et al. (1985) Characterization of immunotoxins active against ovarian cancer cell lines. J Clin Invest 76: 1261–1267PubMedCrossRefGoogle Scholar
  69. Pirker R, Keilhauer G, Raschack M, Lechner C; Ludwig H (1990) Reversal of multi-drug resistance in human KB cell lines by structural analogs of verapamil.Int J Cancer 45: 916–919Google Scholar
  70. Pirker R, Wallner J, Geissler K et al. (1991) MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 83: 708–712PubMedCrossRefGoogle Scholar
  71. Pirker R, Malayeri R, Huber H (1999) Adjuvant and induction chemothera- py in non-small cell lung cancer. Ann Oncol 10 [Suppl 61: 71–76CrossRefGoogle Scholar
  72. Pirker R, Smith R (2002) Darbepoetin alfa: potential role in managing ane- mia in cancer patients. Expert Rev AnticancerTher 2: 377–384CrossRefGoogle Scholar
  73. Plunkett W, Huang P, Gandhi V (1995) Preclinical characteristics of gemcitabine. Anticancer Drugs 6 [Suppl 6]: 7–13PubMedCrossRefGoogle Scholar
  74. Prendergast GC (2000) Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects. Curr Opin Cell Biol 12: 166–173PubMedCrossRefGoogle Scholar
  75. Ratain MJ, Schilsky RL, Conley BA, Egorin MJ (1990) Pharmacodynamics in cancer therapy.) Clin Oncol 8: 1739–1753Google Scholar
  76. RizzoJD,Lichtin AE,Woolf SH et al.,and the American Society of Clinical Oncology, American Society of Hematology (2002) Use of epoetin in pa-Google Scholar
  77. tients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20: 4083–4107Google Scholar
  78. Rosell R, Felip E (2000) Role of multimodality treatment for lung cancer. Semin Surg Oncol 18: 143–151PubMedCrossRefGoogle Scholar
  79. Schiff P, Fant J, Horwitz S (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277: 665PubMedCrossRefGoogle Scholar
  80. Schwartz SA, Morgenstern B, Capizzi RL (1982) Schedule-dependent synergy and antagonism between high-dose 1-beta-D-arabinofuranosylcytosine and asparaginase in the L5,178Y murine Ieukemia.Cancer Res 42: 2191–2197Google Scholar
  81. Shackney SE, McCormack GW, Cuchural GJ (1978) Growth rate patterns of solid tumors and their relation to responsiveness to therapy. Ann Intern Med 89: 107PubMedCrossRefGoogle Scholar
  82. Silver RT, Young RC, Holland JF (1977) Some aspects of modern cancer chemotherapy. Am J Med 63: 772PubMedCrossRefGoogle Scholar
  83. Steel GG (1967) Cell loss as a factor in the growth rate of human tumors. Eur J Cancer 3: 381PubMedCrossRefGoogle Scholar
  84. Stevenson FK (1999) DNA vaccines against cancer:from genes to therapy. Ann Oncol 10: 1413PubMedCrossRefGoogle Scholar
  85. Sugarbaker DJ, Norberto JJ (1998) Multimodality management of malignant pleural mesothelioma.Chest 113 [Suppl 1): 61S - 65SGoogle Scholar
  86. Swisher SG, Roth JA (2000) Gene therapy in lung cancer. Curr Oncol Rep 2: 64–70PubMedCrossRefGoogle Scholar
  87. Tennant TR, Rinker-Schaeffer CW, Stadler WM (2000) Angiogenesis Inhibitors. Curr Oncol Rep 2: 11–16PubMedCrossRefGoogle Scholar
  88. Therasse P,Arbuck SG, Eisenhauer EA et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.) Natl Cancer Inst 92: 205–216CrossRefGoogle Scholar
  89. Vansteenkiste J, Pirker R, Massuti B et al., and Aranesp 980297 Study Group (2002) Double-blind, placebo-controlled, randomized phase Ill trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94: 1211–1220Google Scholar
  90. Vidal Pocket (2000) Arzneimittelinformation VIDAL GmbH, 6020 Innsbruck, S 662–663Google Scholar
  91. Weill D, Mack M, Roth J, Swisher S, Proksch S, Merritt J, Nemunaitis J (2000) Adenoviralmediated p53 gene transfer to non-small cell lung cancer through endobronchial injection.Chest 118: 966–970Google Scholar
  92. Weiner LM (1999) Monoclonal antibody therapy of cancer. Semin Oncol 26 [Suppl 141: 43–51Google Scholar
  93. White AW, Almassy R, Calvert AH et al. (2000) Resistance-modifying agents. 9.(1) synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme Poly(ADP-ribose) polymerase.J Med Chem 43: 4084–4097PubMedCrossRefGoogle Scholar
  94. Yarbro JW (1992) The scientific basis of cancer chemotherapy. In: Perry MC (ed) The chemotherapy source book.Williams & Wilkins, Baltimore, pp 2–14Google Scholar
  95. Yuen AR, Sikic BI (2000) Clinical studies of antisense therapy in cancer. Front Biosci 5: D588PubMedCrossRefGoogle Scholar
  96. Zöchbauer-Müller S, Pirker R, Huber H (1999) Treatment of small cell lung cancer patients. Ann Oncol 10 [Supp16]: 83–91PubMedCrossRefGoogle Scholar
  97. Zujewski J, Horak ID, Bol CJ et al. (2000) Phase I and pharmacokinetic study of famesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 18: 927–941PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • R. Pirker

There are no affiliations available

Personalised recommendations